













Area Drugs and Therapeutics Committee Meeting Minutes		
Wednesday 19 th March 2025 10-12.30pm		
Microsoft Teams Meeting		
Present:	Mehrdad Malekian (Chair) Victoria Gemmell (ProfSec) Alistair Brown Rachael Kelly Colin Angus (Lay Member) Kirsty Macfarlane Christine Carswell Craig Thurtell (from 11am)	Stephanie Dundas Tyra Smyth Graeme Bryson Eimear Gordon (depute for GR) Chris Miller Lorna Templeton (item 8a) Jennifer Bryant (item 8e) Mogese Abbas (item 8b)
1. Apologies:	Gail Richardson, David Semple, Penny Brankin.	
2. Declaration of Interest	Nil	
Item	Notes	Action
3.	Ratification of minutes of <u>January/February 2025</u> meeting These were agreed as a true reflection of the meeting and can be published.	
4.	<u>Matters arising not covered elsewhere on the agenda</u> a) Vabysmo – update awaited b) Thrombolysis and Thrombectomy Pathway (V 1.6) - Mark Barber – update awaited This was approved with no further changes. c) Medicines Related Communications to health boards - Graeme Bryson – update awaited No progress at present and will remain on agenda. d) Major Non Obstetric Haemorrhage Guideline – Andrew Fyfe-update awaited e) Administration of S/C Intermittent Medication in Adult Palliative Care Policy - Linda Johnstone-update awaited f) Ryeqo Clinical Protocol – Mihai Gherghe – update awaited	
5.	<u>ADTC Committee Business</u> Nil	
6.	<u>SMC Advice-CONFIDENTIAL</u> Please see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 10.00 am on Monday 07 April 2025.	
6.1		

	FULL SUBMISSION				
	Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary
	bimekizumab solution for injection in pre-filled syringe and pre-filled pen (Bimzelx)	UCB Pharma Limited	for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.	SMC2698	ACCEPTED RESTRICTED with PAS REFER TO DERM FOR ADVICE
	elafibranor film-coated tablets (Iqirvo)  elafibranor (Iqirvo) - FINAL March 2025.d	Ipsen Ltd	for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.	SMC2714	ACCEPTED with PAS REFER TO GASTRO FOR ADVICE
	alectinib hard capsules (Alecensa)  alectinib (Alecensa) -FINAL March 2025.c	Roche Products Ltd	as monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.	SMC2749	ACCEPTED with PAS AVAIT WoSCAN ADVICE
	RESUBMISSION				
	Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary
	tebentafusp concentrate for solution for infusion (Kimmtrak)	Immunocore Ltd	as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive	SMC2746	NOT RECOMMENDED

	<div> tebentafusp (Kimmtrak) Resub FII</div>		adult patients with unresectable or metastatic uveal melanoma.																						
ABBREVIATED SUBMISSIONS																									
	<table><tr><th>Medicine</th><th>Manufacturer</th><th>Indication in brief</th><th>SMC reference</th><th>Advice Summary</th></tr><tr><td>eplontersen solution for injection in pre-filled pen (Wainzua) <div> eplontersen (Wainzua) Abb FINA</div></td><td>AstraZeneca UK Ltd</td><td>for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.</td><td>SMC2755</td><td>ACCEPTED with PAS AWAIT ADVICE FROM TERTIARY CENTRE</td></tr><tr><td>futibatinib film coated tablets (Lytgobi) <div> futibatinib (Lytgobi) Abb FINAL March 20</div></td><td>Taiho Oncology</td><td>as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.</td><td>SMC2661</td><td>ACCEPTED with PAS AWAIT WoSCAN ADVICE</td></tr><tr><td>dapagliflozin film-coated tablets (Forxiga) <div> dapagliflozin (Forxiga) Abb FINAL</div></td><td>AstraZeneca UK Ltd</td><td>in adults for the treatment of chronic kidney disease (CKD).</td><td>SMC2763</td><td>ACCEPTED RESTRICTED REFER TO RENAL FOR ADVICE</td></tr></table>	Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary	eplontersen solution for injection in pre-filled pen (Wainzua) <div> eplontersen (Wainzua) Abb FINA</div>	AstraZeneca UK Ltd	for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	SMC2755	ACCEPTED with PAS AWAIT ADVICE FROM TERTIARY CENTRE	futibatinib film coated tablets (Lytgobi) <div> futibatinib (Lytgobi) Abb FINAL March 20</div>	Taiho Oncology	as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	SMC2661	ACCEPTED with PAS AWAIT WoSCAN ADVICE	dapagliflozin film-coated tablets (Forxiga) <div> dapagliflozin (Forxiga) Abb FINAL</div>	AstraZeneca UK Ltd	in adults for the treatment of chronic kidney disease (CKD).	SMC2763	ACCEPTED RESTRICTED REFER TO RENAL FOR ADVICE				
Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary																					
eplontersen solution for injection in pre-filled pen (Wainzua) <div> eplontersen (Wainzua) Abb FINA</div>	AstraZeneca UK Ltd	for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	SMC2755	ACCEPTED with PAS AWAIT ADVICE FROM TERTIARY CENTRE																					
futibatinib film coated tablets (Lytgobi) <div> futibatinib (Lytgobi) Abb FINAL March 20</div>	Taiho Oncology	as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	SMC2661	ACCEPTED with PAS AWAIT WoSCAN ADVICE																					
dapagliflozin film-coated tablets (Forxiga) <div> dapagliflozin (Forxiga) Abb FINAL</div>	AstraZeneca UK Ltd	in adults for the treatment of chronic kidney disease (CKD).	SMC2763	ACCEPTED RESTRICTED REFER TO RENAL FOR ADVICE																					
6.2	Updates to NHS LK status on SMC advice Confirmation of SMC advice to NHSLK decision changes & any CEL potential breaches RK outlined designation update for medications that had passed the deadline for a board decision, including Rimegepant & Somapacitan & Vibegron. It was noted that a clinical protocol was expected for Rezafungin, Lebrikizumab and Cabotegravir, and discussions are																								

	<p>ongoing for Ryeqo, Roclanda and Sirolimus. Iptacopan and crovalimab designations updated also, reflecting how use of these medicines would be via National PNH outreach centre.</p> <p>RK presented updated bulletins, some of which will be published to the RDS site, which detail designation updates as presented as part of the Follow Up.</p> <p>A question was raised regarding SMC 2605 Bimekizumab for psoriatic arthritis. This featured in a recently approved NHSL guideline. The designation of this remains outstanding as there was a question around finance. As the committee approved this as part of the guideline approval process, the medicine is approved from an ADTC perspective, and the designation can be updated.</p>	
<p>7.</p> <p>7.1</p>	<p><u>Lanarkshire Formulary / West of Scotland Formulary</u></p> <p>RK presented updated bulletins, some of which will be published to the RDS site, which detail designation updates as presented as part of the Follow Up.</p>	
<p>7.2</p> <p>i.</p> <p>ii.</p>	<p>West of Scotland Formulary Updates</p> <p>Draft Formulary Committee Terms of Reference</p> <p>Draft Chapter Expert Working Groups Terms of Reference</p> <p>GRB gave an update. Plans are moving forward with the regional formulary. Thoughts on feedback mechanisms for chapter development were discussed. It was noted that all formulary decisions will require ratification by each Board, and there may be occasions where a local variation is required. The group agreed that collaborative working will be beneficial.</p>	GRB
<p>8a.</p> <p>i.</p> <p>ii.</p> <p>b.</p> <p>c.</p>	<p>Valproate Prescribing Review Process - Lorna Templeton</p> <p>This was approved with no changes.</p> <p>Valproate- Advice for HCP's When Discussing New Recommendations for Existing Male Patients – Lorna Templeton</p> <p>This was discussed and approved with no changes. It was hoped the MHRA guidance would be available soon, but it was agreed that these were helpful meantime.</p> <p>Developing Treatment Plans for Management of the off label use of Clozapine - Mogese Abbas</p> <p>This was discussed and some clarifications were given regarding blood monitoring and terminology. Although not a common occurrence, the MH teams are experienced in managing these and have used this to guide the development of the document. The document was approved pending the update to terminology.</p> <p>Alteplase Guidance for Patients Requiring Thrombolysis – Alternative to Tenecteplase – Gary Lynas</p> <p>This was discussed. A point was raised in relation to recently approved Hyperacute Stroke Guidance and where this would sit in relation to this. Links between both pieces of guidance may be helpful. It would be helpful to include for use in acute stroke in the title. The committee felt it might be helpful to clarify CI to alteplase and tenecteplase. To return for final noting</p>	

	<p>d. Anti-D Prophylaxis in Pregnancy – Kelly Ann Meldrum This was discussed. A point was raised in that the document advises GP’s are responsible for follow up serology. This requires clarification, as this not believed to be current practice. There were also some comments relating to the use of a variety of fonts and odd spacing in sections. The use of “IU” should be avoided. The committee also requested clarification on the changes made to this version from previous. The document is not approved at this time.</p> <p>e. Antipsychotic Depot and Long-Lasting Injection Guidance – Jennifer Bryant This is an update to an existing guideline. The changes were discussed and felt to be helpful. A comment was raised around communication. This was noted. The document was approved.</p> <p>f. Major Haemorrhage Protocol for Paediatric Patients – Christopher Moultrie This was discussed. It was noted that the document is extensive but will be appreciated by teams. It will need reformatted on correct template if this to be held on Right Decisions website. Clarity was requested on plans for how the document will appear on the website, and if this will be either as whole document or action cards separately. The document is not approved at this time.</p> <p>g Use of Wegovy Obesity – Izzy Howat This was approved with no changes.</p> <p>h. NHSL Asthma Treatment Guide – Andrew Smith This is an update to existing guidance, but represents a substantial change in treatment for asthma. The committee felt the guideline was well written, in a clear format and will be helpful to teams. They were also pleased to acknowledge there have been contributions from a wide range of collaborators. It was noted there are many abbreviations, so a glossary would be helpful. There was a discussion on the choices of inhalers, and points around specific device costs, license status and expiry dates were raised. It was agreed a shorter review time of 6 months would be appropriate to ensure any future updates are captured. It was acknowledged this is an evolving situation. Discussions around finance arrangements for changes to testing in both primary and secondary care and for increased medicine costs with subsequent Board impacts are progressing. The document is to return for final approval</p>	
9.	New Medicine Safety Notifications & Alerts	GRB
	<p>CAS - Home NIL for February https://www.gov.uk/drug-safety-update</p> <p>a. MHRA Update-13/2/25 LINK Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell ▼): review by two specialists is required for initiating valproate but not for male patients already taking valproate This was noted.</p> <p>b. Public Health Register for Anti-Seizure Meds This was noted.</p>	

10. 10.1 10.2	<u>Prescribing Management Board Update</u> Nil Nil	
11.	<u>Medicines for the Treatment of Cancer</u> Nil	
12.	<u>Non-Medical Prescribing Symptomatic Relief Policy</u> This was discussed. A question was raised regarding how the policy works alongside HEPMA. There is a need for clarity on how nurses in non-acute sites would implement the policy as they do not have prescribing permissions. It was suggested to link in with the HEPMA team regarding this. Removal of simple linctus was agreed. Clarity was requested on the use of bisacodyl suppositories in combination with glyceryl suppositories	
13.	<u>PGD Activity Report</u> <u>To check</u> KM gave a verbal update Contact has been made with authors of previously identified past review date PGD's. The database is now functional with more to do regarding audit and review. A suggestion was made regarding an amnesty for any other existing PGD's. As the scale of this is unknown, GB will take this forward with senior nursing teams.	
14.	<u>Antimicrobial Management Team Update</u> Nil	
15.	<u>Lay member related items</u> CA is hoping to be able to have a deputy to attend in the event of absence.	
16. a.	<u>AOCB</u> <u>Anticoagulant Guidelines-Update-Eimear Gordon</u> EG gave an update to a previous item regarding the availability of a variety of VTE risk assessments with conflicting advice. Plans to rectify this are underway. In addition, it was noted that there is currently no guidance for either VTE prophylaxis or treatment in extremes of body weight. A SLWG has been created and will take this forward alongside plans for massive PE guidance. The changes in extended dosing advice for patients in up to 150kg weight with apixaban were discussed and as well as the potential for cost efficiencies. Announcement of Committee Retiral MM will be stepping down as ADTC Chair. GB gave thanks on behalf of the committee and appreciated all his help and guidance over the past 12 years.	
17.	<u>Date of next meeting</u> Wednesday 23 rd April 2025 10-12.30pm MS TEAMS	